Institution
Flinders University
Education•Adelaide, South Australia, Australia•
About: Flinders University is a education organization based out in Adelaide, South Australia, Australia. It is known for research contribution in the topics: Population & Health care. The organization has 12033 authors who have published 32831 publications receiving 973172 citations. The organization is also known as: Flinders University of South Australia.
Topics: Population, Health care, Poison control, Palliative care, Mental health
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Results indicated that the negativity directed at successful female managers--in ratings of likability, interpersonal hostility, and boss desirability--was mitigated when there was indication that they were communal.
Abstract: In 3 experimental studies, the authors tested the idea that penalties women incur for success in traditionally male areas arise from a perceived deficit in nurturing and socially sensitive communal attributes that is implied by their success. The authors therefore expected that providing information of communality would prevent these penalties. Results indicated that the negativity directed at successful female managers--in ratings of likability, interpersonal hostility, and boss desirability--was mitigated when there was indication that they were communal. This ameliorative effect occurred only when the information was clearly indicative of communal attributes (Study 1) and when it could be unambiguously attributed to the female manager (Study 2); furthermore, these penalties were averted when communality was conveyed by role information (motherhood status) or by behavior (Study 3). These findings support the idea that penalties for women's success in male domains result from the perceived violation of gender-stereotypic prescriptions.
765 citations
••
TL;DR: This review will present recent research on surface modifications of PDMS using techniques ranging from metal layer coatings and layer‐by‐layer depositions to dynamic surfactant treatments and the adsorption of amphipathic proteins.
Abstract: PDMS is enjoying continued and ever increasing popularity as the material of choice for microfluidic devices due to its low cost, ease of fabrication, oxygen permeability and optical transparency. However, PDMS's hydrophobicity and fast hydrophobic recovery after surface hydrophilization, attributed to its low glass transition temperature of less than -120 degrees C, negatively impacts on the performance of PDMS-based microfluidic device components. This issue has spawned a flurry of research to devise longer lasting surface modifications of PDMS, with particular emphasis on microfluidic applications. This review will present recent research on surface modifications of PDMS using techniques ranging from metal layer coatings and layer-by-layer depositions to dynamic surfactant treatments and the adsorption of amphipathic proteins. We will also discuss significant advances that have been made with a broad palette of gas-phase processing methods including plasma processing, sol-gel coatings and chemical vapor deposition. Finally, we will present examples of applications and future prospects of modified PDMS surfaces in microfluidics, in areas such as molecular separations, cell culture in microchannels and biomolecular detection via immunoassays.
749 citations
••
TL;DR: Data is presented that shows perfectionism increases vulnerability for eating disorders, and that it maintains obsessive-compulsive disorder, social anxiety and depression as it predicts treatment outcome in these disorders.
713 citations
••
TL;DR: Examination of second stage DEA efficiency analyses, within the context of a censoring data generating process (DGP) and a fractional data DGP, when efficiency scores are treated as descriptive measures of the relative performance of units in the sample suggests Tobit estimation in this situation is inappropriate.
705 citations
••
Katholieke Universiteit Leuven1, Ottawa Hospital Research Institute2, University of Turin3, University of Bern4, Cliniques Universitaires Saint-Luc5, Bristol-Myers Squibb6, Peter MacCallum Cancer Centre7, University of Melbourne8, University of Sydney9, Flinders University10, Catholic University of Leuven11
TL;DR: In this paper, the authors studied the association between KRAS mutation status (p.G13D vs other KRAS mutations) and response and survival in a pooled data set of 579 patients with metastatic colorectal cancer treated with cetuximab between 2001 and 2008.
Abstract: Context Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Objective To test the hypothesis that KRAS codon 13 mutations are associated with a better outcome after treatment with cetuximab than observed with other KRAS mutations. Design, Setting, and Patients We studied the association between KRAS mutation status (p.G13D vs other KRAS mutations) and response and survival in a pooled data set of 579 patients with chemotherapy-refractory colorectal cancer treated with cetuximab between 2001 and 2008. Patients were included in the CO. 17, BOND, MABEL, EMR202600, EVEREST, BABEL, or SALVAGE clinical trials or received off-study treatment. Univariate and multivariate analyses, adjusting for possible prognostic factors and data set, were performed. The effect of the different mutations was studied in vitro by constructing isogenic cell lines with wild-type KRAS, p.G12V, or p.G13D mutant alleles and treating them with cetuximab. Main Outcome Measures The main efficacy end point was overall survival. Secondary efficacy end points were response rate and progression-free survival. Results In comparison with patients with other KRAS-mutated tumors, patients with p.G13D-mutated tumors (n=32) treated with cetuximab had longer overall survival (median, 7.6 [95% confidence interval {CI}, 5.7-20.5] months vs 5.7 [95% CI, 4.9-6.8] months; adjusted hazard ratio [HR], 0.50; 95% CI, 0.31-0.81; P=.005) and longer progression-free survival (median, 4.0 [95% CI, 1.9-6.2] months vs 1.9 [95% CI, 1.8-2.8] months; adjusted HR, 0.51; 95% CI, 0.32-0.81; P=.004). There was a significant interaction between KRAS mutation status (p.G13D vs other KRAS mutations) and overall survival benefit with cetuximab treatment (adjusted HR, 0.30; 95% CI, 0.14-0.67; P=.003). In vitro and mouse model analysis showed that although p.G12V-mutated colorectal cells were insensitive to cetuximab, p.G13D-mutated cells were sensitive, as were KRAS wild-type cells. Conclusions In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors. Evaluation of cetuximab therapy in these tumors in prospective randomized trials may be warranted. JAMA. 2010; 304(16): 1812-1820
702 citations
Authors
Showing all 12221 results
Name | H-index | Papers | Citations |
---|---|---|---|
Matthew Jones | 125 | 1161 | 96909 |
Robert Edwards | 121 | 775 | 74552 |
Justin C. McArthur | 113 | 433 | 47346 |
Peter Somogyi | 112 | 232 | 42450 |
Glenda M. Halliday | 111 | 676 | 53684 |
Jonathan C. Craig | 108 | 872 | 59401 |
Bruce Neal | 108 | 561 | 87213 |
Alan Cooper | 108 | 746 | 45772 |
Robert J. Norman | 103 | 755 | 45147 |
John B. Furness | 103 | 597 | 37668 |
Richard J. Miller | 103 | 419 | 35669 |
Michael J. Brownstein | 102 | 274 | 47929 |
Craig S. Anderson | 101 | 650 | 49331 |
John Chalmers | 99 | 831 | 55005 |
Kevin D. Hyde | 99 | 1382 | 46113 |